Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
As of today, Incyte(INCY) shares are valued at $129.46. The company's market cap stands at 25.96B, with a P/E ratio of 16.50.
During the trading session on 2026-07-28, Incyte(INCY) shares reached a daily high of $131.34 and a low of $118.00. At a current price of $129.46, the stock is +9.7% higher than the low and still -1.4% under the high.
Trading activity shows a volume of 2.79M, compared to an average daily volume of 1.55M.
The stock's 52-week range extends from a low of $69.70 to a high of $131.34.
The stock's 52-week range extends from a low of $69.70 to a high of $131.34.
INCY News
(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio....
...
Shares of Prelude Therapeutics (PRLD) after moving higher after Incyte (INCY) in its Q2 earnings release that after a review of available data, it has discontin...
Analyst ratings
55%
of 29 ratingsMore INCY News
Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per...
Reports Q2 revenue $1.67B, consensus $1.49B. “Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business deve...
Advertisement Why Incyte Stock Is Back in Focus Incyte (INCY) is back on investor watchlists after publishing full safety and efficacy results from its Phase...
In July 2026, Halozyme Therapeutics announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989, using...
William Blair analyst Matt Phipps has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Claim 55% Off TipRanks Unlock powerful inve...
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Incyte today and set a price target of $140.00. Claim 55% Off TipRanks Unlock powerful invest...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.